Evaluation of Punicalagin as a multi-targeted therapeutic agent against endometrial cancer
Zeeshan Ahmad Bhutta, Dohee Ahn, Hong Kyu Lee, Kyung-Chul Choi · 2026
Read Evaluation of Punicalagin as a multi-targeted therapeutic agent against endometrial cancer by Zeeshan Ahmad Bhutta, Dohee Ahn, Hong Kyu Lee, Kyung-Chul Choi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13471133.txt.
Description
Zeeshan Ahmad Bhutta, Dohee Ahn, Hong Kyu Lee, and Kyung-Chul Choi evaluate in 2026 a pomegranate compound as a candidate treatment for endometrial cancer. This womb cancer is growing more common, and advanced or returning cases have few options. The compound, punicalagin, was tested on two endometrial cancer cell lines and in mice carrying human tumors.
Rising doses slowed cell growth and colony formation, and the compound blocked cell migration while restoring a marker of cells staying put, a shift against spread. Treated cells lost mitochondrial voltage, built up reactive oxygen, and died by programmed death with raised death signals. Signs of self digestion appeared too, strongest in one cell line. In mice, tumors shrank in volume and weight while body weight held steady. The authors call for further preclinical and clinical study.
Catalog record
| CREATOR | Zeeshan Ahmad Bhutta, Dohee Ahn, Hong Kyu Lee, Kyung-Chul Choi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38520 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |